Abstract
Atherosclerosis has been widely recognized as a slow progressing inflammatory disease of the arterial walls involving both inflammation and autoimmune processes with a complex etiology in which the immune system plays a key role. A hallmark of atherosclerosis is that the macrophages pick up the lipids to form the foam cells which build up the plaque in the arterial wall. Consequently, the arteries become narrowed.
Plaque rupture can trigger thrombosis which is superimposed on atherosclerotic lesion. The activation of macrophages and T cells plays key roles in these lesions. Cells involved in the atherosclerotic process secrete soluble factors, known as cytokines. These cytokines can be further divided into two classes namely proinflammatory and anti-inflammatory cytokines based on their roles in inflammation. Among the cytokines, interleukin (IL)-35 is the one most recently discovered that suppresses inflammatory responses of immune cells. Accumulating evidence suggests that IL-35 represents an attractive target for antiatherosclerotic therapy based on its several atheroprotective features. In this review, we will provide a brief overview of IL-35 biology and the role of IL-35 in the development, or the progression of atherosclerosis.
Keywords: IL-35, atherosclerosis, regulation t cell, knock out mice and cytokine.
Current Pharmaceutical Design
Title:The role of interleukin 35 in atherosclerosis
Volume: 21 Issue: 35
Author(s): Juntang Lin, Vijay Kakkar and Xinjie Lu
Affiliation:
Keywords: IL-35, atherosclerosis, regulation t cell, knock out mice and cytokine.
Abstract: Atherosclerosis has been widely recognized as a slow progressing inflammatory disease of the arterial walls involving both inflammation and autoimmune processes with a complex etiology in which the immune system plays a key role. A hallmark of atherosclerosis is that the macrophages pick up the lipids to form the foam cells which build up the plaque in the arterial wall. Consequently, the arteries become narrowed.
Plaque rupture can trigger thrombosis which is superimposed on atherosclerotic lesion. The activation of macrophages and T cells plays key roles in these lesions. Cells involved in the atherosclerotic process secrete soluble factors, known as cytokines. These cytokines can be further divided into two classes namely proinflammatory and anti-inflammatory cytokines based on their roles in inflammation. Among the cytokines, interleukin (IL)-35 is the one most recently discovered that suppresses inflammatory responses of immune cells. Accumulating evidence suggests that IL-35 represents an attractive target for antiatherosclerotic therapy based on its several atheroprotective features. In this review, we will provide a brief overview of IL-35 biology and the role of IL-35 in the development, or the progression of atherosclerosis.
Export Options
About this article
Cite this article as:
Lin Juntang, Kakkar Vijay and Lu Xinjie, The role of interleukin 35 in atherosclerosis, Current Pharmaceutical Design 2015; 21 (35) . https://dx.doi.org/10.2174/1381612821666150915111125
DOI https://dx.doi.org/10.2174/1381612821666150915111125 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multifunctional RNase MCPIP1 and its Role in Cardiovascular Diseases
Current Medicinal Chemistry Insight to the Pathophysiology of Stable Angina Pectoris
Current Pharmaceutical Design Utilization of the DaT-SCAN SPECT in the Diagnosis of Parkinson's Disease in Older Subjects
Letters in Drug Design & Discovery Regulatory Cascade of Neuronal Loss and Glucose Metabolism
CNS & Neurological Disorders - Drug Targets Mechanisms of Cardiovascular Changes in an Experimental Model of Syndrome X and Pharmacological Intervention on the Renin-Angiotensin- System
Current Vascular Pharmacology Nitrogen Containing Privileged Structures and their Solid Phase Combinatorial Synthesis
Combinatorial Chemistry & High Throughput Screening Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders
Current Pharmaceutical Design Physiological Effect and Therapeutic Application of Alpha Lipoic Acid
Current Medicinal Chemistry Pharmacological Treatment of Obesity, Food Intake, and Reversal of Metabolic Disorders
Current Nutrition & Food Science The Fibroblast Growth Factor 23: A New Player in the Field of Cardiovascular, Bone and Renal Disease
Current Vascular Pharmacology Oxidative DNA Damage and Oxidant/Anti-Oxidant Enzymatic Systems in Carcinogenesis and Cancer Progression
Current Enzyme Inhibition Restless Leg Syndrome Associated with Atypical Antipsychotics: Current Status, Pathophysiology, and Clinical Implications
Current Drug Safety Assessment of Vascular Geometry for Bilateral Carotid Artery Ligation to Induce Early Basilar Terminus Aneurysmal Remodeling in Rats
Current Neurovascular Research Neuroimaging of the Vulnerable Plaque
Current Vascular Pharmacology Directions for Enhancement of the Therapeutic Efficacy of Mesenchymal Stem Cells in Different Neurodegenerative and Cardiovascular Diseases: Current Status and Future Perspectives
Current Stem Cell Research & Therapy Hyperglycaemia and Vitamin D: A Systematic Overview
Current Diabetes Reviews Non-Viral Delivery of RNA Interference Targeting Cancer Cells in Cancer Gene Therapy
Current Gene Therapy Repurposed Drugs in Metabolic Disorders
Current Topics in Medicinal Chemistry Emerging Pharmacological Treatments to Prevent Abdominal Aortic Aneurysm Growth and Rupture
Current Pharmaceutical Design Bleeding, Vertebral Fractures and Vascular Calcifications in Patients Treated with Warfarin: Hope for Lower Risks with Alternative Therapies
Current Vascular Pharmacology